Cargando…

Corona-Impfstoffe im Überfluss — was dann?

A total of 3.2 million people in Germany have been fully immunised so far. However, in order to achieve herd immunity, which is likely to require an immunisation rate of around 80 % due to the highly infectious mutants, approximately 65 million people need to be vaccinated. The current “imbalance” i...

Descripción completa

Detalles Bibliográficos
Autores principales: Cassel, Dieter, Ulrich, Volker
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052199/
https://www.ncbi.nlm.nih.gov/pubmed/33897057
http://dx.doi.org/10.1007/s10273-021-2895-4
_version_ 1783679879459373056
author Cassel, Dieter
Ulrich, Volker
author_facet Cassel, Dieter
Ulrich, Volker
author_sort Cassel, Dieter
collection PubMed
description A total of 3.2 million people in Germany have been fully immunised so far. However, in order to achieve herd immunity, which is likely to require an immunisation rate of around 80 % due to the highly infectious mutants, approximately 65 million people need to be vaccinated. The current “imbalance” in the vaccination campaign is largely due to the limited supply of vaccines. Since J&J’s vaccine has recently been approved by the EU and additional production facilities are available, it is foreseeable that the capacities of the vaccination centres will no longer be sufficient. Moreover, at some point the existing unwillingness to vaccinate could become the final bottleneck in reaching herd immunity. This paper provides some calculations for these relationships. Against this background, it is questionable how well-prepared the present system is to cope with these foreseeable problems.
format Online
Article
Text
id pubmed-8052199
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-80521992021-04-19 Corona-Impfstoffe im Überfluss — was dann? Cassel, Dieter Ulrich, Volker Wirtschaftsdienst Analysen und Berichte A total of 3.2 million people in Germany have been fully immunised so far. However, in order to achieve herd immunity, which is likely to require an immunisation rate of around 80 % due to the highly infectious mutants, approximately 65 million people need to be vaccinated. The current “imbalance” in the vaccination campaign is largely due to the limited supply of vaccines. Since J&J’s vaccine has recently been approved by the EU and additional production facilities are available, it is foreseeable that the capacities of the vaccination centres will no longer be sufficient. Moreover, at some point the existing unwillingness to vaccinate could become the final bottleneck in reaching herd immunity. This paper provides some calculations for these relationships. Against this background, it is questionable how well-prepared the present system is to cope with these foreseeable problems. Springer Berlin Heidelberg 2021-04-17 2021 /pmc/articles/PMC8052199/ /pubmed/33897057 http://dx.doi.org/10.1007/s10273-021-2895-4 Text en © Der/die Autor:in(nen) 2021 https://creativecommons.org/licenses/by/4.0/Open Access: Dieser Artikel wird unter der Creative Commons Namensnennung 4.0 International Lizenz veröffentlicht (https://creativecommons.org/licenses/by/4.0/deed.de (https://creativecommons.org/licenses/by/4.0/) ). Open Access wird durch die ZBW — Leibniz-Informationszentrum Wirtschaft gefördert.
spellingShingle Analysen und Berichte
Cassel, Dieter
Ulrich, Volker
Corona-Impfstoffe im Überfluss — was dann?
title Corona-Impfstoffe im Überfluss — was dann?
title_full Corona-Impfstoffe im Überfluss — was dann?
title_fullStr Corona-Impfstoffe im Überfluss — was dann?
title_full_unstemmed Corona-Impfstoffe im Überfluss — was dann?
title_short Corona-Impfstoffe im Überfluss — was dann?
title_sort corona-impfstoffe im überfluss — was dann?
topic Analysen und Berichte
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052199/
https://www.ncbi.nlm.nih.gov/pubmed/33897057
http://dx.doi.org/10.1007/s10273-021-2895-4
work_keys_str_mv AT casseldieter coronaimpfstoffeimuberflusswasdann
AT ulrichvolker coronaimpfstoffeimuberflusswasdann